Top

Published in:

01-02-2024 | Heart Failure

Investigating the place of sodium-glucose cotransporter-2 inhibitors and dual sodium-glucose cotransporter-1 and dual sodium-glucose cotransporter-2 inhibitors in heart failure therapy: a systematic review of the literature

Authors: Taylor McKenzie, Genevieve M. Hale, Amelia Miner, Jean Colón Colón, Garrett Evins, Jasmine Wade

Published in: Heart Failure Reviews | Issue 2/2024

Abstract

Sodium-glucose cotransporter-2 inhibitors have been shown to have significant metabolic, renal, and atherosclerotic cardiovascular disease benefits. Recent randomized controlled trials have extended these benefits to patients with heart failure. In fact, the robust findings from these studies in patients with any type of heart failure have led to the incorporation of this drug class in currently updated evidence-based guidelines for this condition. However, given the novelty in utilizing these agents in heart failure, there is uncertainty regarding place in therapy and sequencing in treatment. As such, this review aims to summarize existing literature to guide practitioners regarding the use of these agents in the management of heart failure.

Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS (2023) Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res 119(6):1453. https://doi.org/10.1093/cvr/cvac013CrossRef

Scheen AJ (2015) Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 75(1):33–59. https://doi.org/10.1007/s40265-014-0337-yCrossRefPubMed

Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF (2012) Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomized controlled trial. Int J Clin Pract 66(5):446–456. https://doi.org/10.1111/j.1742-1241.2012.02911.xCrossRefPubMed

Roden M, Merker L, Christiansen AV et al (2015) Safety, tolerability, and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial. Cardiovasc Diabetol 14:154. https://doi.org/10.1186/s12933-015-0314-0CrossRefPubMedPubMedCentral

Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117–2128. https://doi.org/10.1056/NEJMoa1504720CrossRefPubMed

Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644–657. https://doi.org/10.1056/NEJMoa1611925CrossRefPubMed

Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347–357. https://doi.org/10.1056/NEJMoa1812389CrossRefPubMed

Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295–2306. https://doi.org/10.1056/NEJMoa1811744CrossRefPubMed

McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995–2008. https://doi.org/10.1056/NEJMoa1911303CrossRefPubMed

10.

Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413–1424. https://doi.org/10.1056/NEJMoa2022190CrossRefPubMed

11.

Anker SD, Butler J, Filippatos G et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385(16):1451–1461. https://doi.org/10.1056/NEJMoa2107038CrossRefPubMed

12.

Solomon SD, McMurray JJV, Claggett B et al (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387(12):1089–1098. https://doi.org/10.1056/NEJMoa2206286CrossRefPubMed

13.

Heidenreich PA, Bozkurt B, Aguilar D et al (2022) 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145:e895–e1032. https://doi.org/10.1161/CIR.0000000000001063CrossRefPubMed

14.

Bhatt DL, Szarek M, Pitt B et al (2021) Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med 384(2):129–139. https://doi.org/10.1056/NEJMoa2030186CrossRefPubMed

15.

Herrington WG, Staplin N, Wanner C et al (2023) Empagliflozin in patients with chronic kidney disease. N Engl J Med 388(2):117–127. https://doi.org/10.1056/NEJMoa2204233CrossRefPubMed

16.

Butler J, Packer M, Filippatos G et al (2022) Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur Heart J 43(5):416–426. https://doi.org/10.1093/eurheartj/ehab798CrossRefPubMed

17.

Zannad F, Ferreira JP, Pocock SJ et al (2020) SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 396(10254):819–829. https://doi.org/10.1016/S0140-6736(20)31824-9CrossRefPubMed

18.

Sotagliflozin tablets, for oral use. [Prescribing Information]. Lexicon Pharmaceuticals, Inc https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216203s000lbl.pdf. Revised May 2023. Accessed October 13, 2023

19.

Täger T, Frankenstein L, Atar D et al (2022) Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis. Clin Res Cardiol 111(4):428–439. https://doi.org/10.1007/s00392-021-01913-zCrossRefPubMed

20.

Bhatt DL, Szarek M, Steg PG et al (2021) Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 384(2):117–128. https://doi.org/10.1056/NEJMoa2030183CrossRefPubMed

21.

Koufakis T, Doumas M, Zebekakis P, Kotsa K (2022) Dual sodium-glucose cotransporter (SGLT) 1/2 versus pure SGLT2 inhibitors: two distinct drug categories or one class with multiple faces? Expert Opin Pharmacother 23(13):1497–1502. https://doi.org/10.1080/14656566.2022.2113385CrossRefPubMed

22.

Pollack R, Cahn A (2022) SGLT2 inhibitors and safety in older patients. Heart Fail Clin 18(4):635–643. https://doi.org/10.1016/j.hfc.2022.03.002CrossRefPubMed

23.

Evans M, Morgan AR, Davies S, Beba H, Strain WD (2022) The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus. Age Ageing 51(10):afac201. https://doi.org/10.1093/ageing/afac201

24.

Docherty KF, McMurray JJV (2022) Foundational drugs for HFrEF: the growing evidence for a rapid sequencing strategy. Br J Cardiol 29(1):2. Published 2022 Jan 12. https://doi.org/10.5837/bjc.2022.002

25.

Carluccio E, Biagioli P, Reboldi G et al (2023) Left ventricular remodeling response to SGLT2 inhibitors in heart failure: an updated meta-analysis of randomized controlled studies. Cardiovasc Diabetol 22(1):235. https://doi.org/10.1186/s12933-023-01970-wCrossRefPubMedPubMedCentral

26.

Daubert MA, Adams K, Yow E et al (2019) NT-proBNP goal achievement is associated with significant reverse remodeling and improved clinical outcomes in HFrEF. JACC Heart Fail 7(2):158–168. https://doi.org/10.1016/j.jchf.2018.10.014CrossRefPubMed

27.

Oates CP, Santos-Gallego CG, Smith A et al (2023) SGLT2 inhibitors reduce sudden cardiac death risk in heart failure: meta-analysis of randomized clinical trials. J Cardiovasc Electrophysiol 34(5):1277–1285. https://doi.org/10.1111/jce.15894CrossRefPubMed

28.

Krum H, Roecker EB, Mohacsi P et al (2003) Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA 289(6):712–718. https://doi.org/10.1001/jama.289.6.712CrossRefPubMed

29.

McMurray JJV, Packer M (2021) How should we sequence the treatments for heart failure and a reduced ejection fraction? Circulation 143:8757. https://doi.org/10.1161/CIRCULATIONAHA.120.052926CrossRef

30.

Packer M, McMurray JJV (2021) Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction. Eur J Heart Fail 23:882–894. https://doi.org/10.1002/ejhf.2149

31.

Dixit NM, Ziaeian B, Fonarow GC (2022) SGLT2 inhibitors in heart failure: early initiation to achieve rapid clinical benefits. Heart Fail Clin 18(4):587–596. https://doi.org/10.1016/j.hfc.2022.03.003CrossRefPubMed

32.

Packer M, Poole-Wilson PA, Armstrong PW et al (1999) Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 100:2312–2318. https://doi.org/10.1161/01.CIR.100.23.2312CrossRefPubMed

33.

Konstam MA, Neaton JD, Dickstein K et al (2009) Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomized, double-blind trial. Lancet 374:1840–1848. https://doi.org/10.1016/S0140-6736(09)61913-9CrossRefPubMed

34.

Docherty KF, Jhund PS, Inzucchi SE et al (2020) Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. Eur Heart J 41(25):2379–2392. https://doi.org/10.1093/eurheartj/ehaa183CrossRefPubMedPubMedCentral

35.

Willenheimer R, van Veldhuisen DJ, Silke B et al (2005) Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 112(16):2426–2435. https://doi.org/10.1161/CIRCULATIONAHA.105.582320CrossRefPubMed

36.

McMurray JJ, Packer M, Desai AS et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993–1004. https://doi.org/10.1056/NEJMoa1409077CrossRefPubMed

Title: Investigating the place of sodium-glucose cotransporter-2 inhibitors and dual sodium-glucose cotransporter-1 and dual sodium-glucose cotransporter-2 inhibitors in heart failure therapy: a systematic review of the literature
Authors: Taylor McKenzie
Genevieve M. Hale
Amelia Miner
Jean Colón Colón
Garrett Evins
Jasmine Wade
Publication date: 01-02-2024
Publisher: Springer US
Keywords: Heart Failure
Empagliflozin
Dapagliflozin
Canagliflozin
Chronic Kidney Disease
Published in: Heart Failure Reviews / Issue 2/2024
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-024-10388-9

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Investigating the place of sodium-glucose cotransporter-2 inhibitors and dual sodium-glucose cotransporter-1 and dual sodium-glucose cotransporter-2 inhibitors in heart failure therapy: a systematic review of the literature

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2024

The role and application of current pharmacological management in patients with advanced heart failure

Can the hemodynamic model in heart failure be restored based on analysis of ventricular-arterial coupling?

Multidisciplinary approach in cardiomyopathies: From genetics to advanced imaging

Correction to: Clinical staging of Anderson‑Fabry cardiomyopathy: an operative proposal

The prevalence of coronary microvascular dysfunction (CMD) in heart failure with preserved ejection fraction (HFpEF): a systematic review and meta-analysis

Anti-bradycardia pacing—impact on patients with HFpEF: a systematic review

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page